Ad Header



The Pulse of the Pharmaceutical Industry

U.S. District Court rules in favor of Lilly’s Alimta patent

Written by: | | Dated: Friday, June 22nd, 2018


Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India’s Dr. 

The patent for Lilly’s top-selling cancer drug will expire in May 2022.

“Lilly’s extensive research to discover the Alimta vitamin regimen patent deserves intellectual property protection,” Lilly’s senior vice president Michael Harrington said in a statement.

Lilly has faced several legal challenges to its right to avoid generic competition for Alimta, whose chemical name is pemetrexed.


(Reporting by Vibhuti Sharma in Bengaluru; Editing by Arun Koyyur)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom